Please assess the completion status of the following clinical trial:

Trial Title: Catalysing the Containment of COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults \>18 years of age.~2. Confirmed COVID-19 on antigen testing\* and/or RT-PCR using NP or OP swabs (or sputum or another sample e.g. stool).~   * Only SAHPRA approved antigen tests will be used to identify COVID-19. A positive antigen detection test will be valid provided that at least one serial PCR test is positive.~3. Presenting within 6 days of symptom onset.~4. Not requiring immediate hospitalisation.~5. Patients with non-severe not requiring admission i.e. mild disease (respiratory rate \<25/min), pulse rate \<120 beats/min, oxygen saturation of ≥93% at sea level sites and \>91% at high altitude sites)~6. Enhanced risk and/or HIV-infected~Exclusion Criteria:~1. Refusal or unable to sign informed consent.~2. Patient who declines or will be unable to comply with follow up visits by study staff.~3. Patients with advanced organ dysfunction/co-morbid conditions that in the opinion of the study doctor would compromise the patient's well-being.~4. Patients who have had symptoms for \> 6 days (as at the day of recruitment).~5. Patients who refuse HIV-testing.~6. Patients using warfarin (Appendix A in the protocol)~7. Patients with a body weight of less than 40kg.~8. Women of child-bearing age (18-50 years) with a positive urine pregnancy test at randomisation.~9. Female patients who are currently breastfeeding.~10. Patients without HIV infection or at least one enhanced risk characteristic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Nitazoxanide (Type: EXPERIMENTAL): Nitazoxaninde, 1000mg (2pills), oral, twice daily for 7 days. To be taken with food.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 2 pills, oral, twice daily for 7 days. To be taken with food.

Based on this trial design, predict the completion outcome and termination type (if applicable).